Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

The landscape of cancer research and cancer care in China

Nature Medicine volume 29, pages 3022–3032 (2023)Cite this article

Subjects

Abstract

The rising cancer incidence rate in China poses a substantial public health concern, although there have been remarkable improvements in the country’s cancer mortality and survival rates. In this Review, we outline the current landscape and future directions of cancer care and research in China. We discuss national screening programs and strategies for cancer detection and delve into the evolving landscape of cancer care, emphasizing the adoption of multidisciplinary, comprehensive treatment and precision oncology. Additionally, we examine changes in drug research and development policies that have enabled approval of new drugs. Finally, we look to the future, highlighting key priorities and identifying gaps. Effectively addressing challenges and seizing opportunities associated with cancer research in China will enable the development of targeted approaches to alleviate the global burden of cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The development of MDTs in China.
Fig. 2: Current status of precision oncology in China.
Fig. 3: Overview of the anti-tumor drug development pipeline for solid tumors in China from 2015 to 2022.
Fig. 4: Overview of cell therapy development for solid tumors in China from 2015 to 2022.

Similar content being viewed by others

Data availability

All data relevant to the study are included in the article.

Code availability

Not applicable.

References

  1. Zheng, R. et al. Cancer incidence and mortality in China, 2016. J. Natl Cancer Cent. 2, 1–9 (2022).

    Google Scholar 

  2. Chen, R. et al. Patterns and trends in esophageal cancer incidence and mortality in China: an analysis based on cancer registry data. J. Natl Cancer Cent. 3, 21–27 (2023).

    CAS  Google Scholar 

  3. Cao, M. et al. Epidemiological trend analysis of gastric cancer in China from 2000 to 2019. Chin. J. Dig. Surg. 20, 102–109 (2021).

    Google Scholar 

  4. Zheng, R. et al. Liver cancer incidence and mortality in China: temporal trends and projections to 2030. Chin. J. Cancer Res. 30, 571–579 (2018).

    PubMed  PubMed Central  Google Scholar 

  5. Zeng, H. et al. Changing cancer survival in China during 2003–15: a pooled analysis of 17 population-based cancer registries. Lancet Glob. Health 6, e555–e567 (2018).

    PubMed  Google Scholar 

  6. Weeden, C. E., Hill, W., Lim, E. L., Gronroos, E. & Swanton, C. Impact of risk factors on early cancer evolution. Cell 186, 1541–1563 (2023).

    CAS  PubMed  Google Scholar 

  7. The Central People’s Government of the People’s Republic of China. Healthy China 2030. www.gov.cn/zhengce/2016-10/25/content_5124174.htm (2016).

  8. Chen, W. et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66, 115–132 (2016).

    PubMed  Google Scholar 

  9. Xia, C. et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants. Chin. Med. J. 135, 584–590 (2022).

    PubMed  PubMed Central  Google Scholar 

  10. Lu, Z. et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. B MJ 377, e068714 (2022).

    Google Scholar 

  11. He, J. et al. [China guideline for the screening, early detection and early treatment of liver cancer (2022, Beijing)]. Zhonghua Zhong Liu Za Zhi 31, 587–631 (2022).

    Google Scholar 

  12. Zhao, F. & Qiao, Y. Cervical cancer prevention in China: a key to cancer control. Lancet 393, 969–970 (2019).

    PubMed  Google Scholar 

  13. Crosby, D. et al. Early detection of cancer. Science 375, eaay9040 (2022).

    CAS  PubMed  Google Scholar 

  14. National Health Commission of the People’s Republic of China. National Plan for Prevention and Treatment of Chronic Diseases (2012–2015). www.nhc.gov.cn/wjw/gfxwj/201304/b8de7b7415ca4996b3567e5a09e43300.shtml (2012).

  15. Romero, D. Genetics: oesophageal cancer — not all alike. Nat. Rev. Clin. Oncol. 14, 138 (2017).

  16. The Central People’s Government of the People’s Republic of China. Healthy China (2019–2030). www.gov.cn/xinwen/2019-07/15/content_5409694.htm (2019).

  17. Cao, M. et al. Cancer screening in China: the current status, challenges, and suggestions. Cancer Lett. 506, 120–127 (2021).

    CAS  PubMed  Google Scholar 

  18. Dai, M., Shi, J. F. & Ni, L. The design and expectation of the cancer screening program in urban China. J. Chin. J. Prev. Med. 47, 179–182 (2013).

    Google Scholar 

  19. Chen, R. et al. Effectiveness of one-time endoscopic screening programme in prevention of upper gastrointestinal cancer in China: a multicentre population-based cohort study. Gut 70, 251–260 (2021).

    PubMed  Google Scholar 

  20. National Health Commission of the People’s Republic of China. Reply to Proposal No.4160 of the First Session of the 13th National People’s Congress. www.nhc.gov.cn/wjw/jiany/201901/0f95ef7a588e4920a8c588878e248753.shtml (2019).

  21. National Health Commission of the People’s Republic of China. Reply to Proposal No. 2941 (Medical and Sports 355) of the Fifth Session of the 12th National Committee of the Chinese People’s Political Consultative Conference. www.nhc.gov.cn/wjw/tia/201801/eec6b89d0ed44c338ead262694dffa3b.shtml (2018).

  22. Chen, W. et al. Preliminary analysis of cancer screening program in urban China from 2013 to 2017. China Cancer 29, 1–6 (2020).

    Google Scholar 

  23. Zhang, B. H., Yang, B. H. & Tang, Z. Y. Randomized controlled trial of screening for hepatocellular carcinoma. J. Cancer Res. Clin. Oncol. 130, 417–422 (2004).

    PubMed  Google Scholar 

  24. Zhang, J. et al. Effectiveness of high-risk human papillomavirus testing for cervical cancer screening in China: a multicenter, open-label, randomized clinical trial. JAMA Oncol. 7, 263–270 (2021).

    PubMed  Google Scholar 

  25. Ji, M. F. et al. Incidence and mortality of nasopharyngeal carcinoma: interim analysis of a cluster randomized controlled screening trial (PRO-NPC-001) in southern China. Ann. Oncol. 30, 1630–1637 (2019).

    CAS  PubMed  Google Scholar 

  26. He, Z. et al. Efficacy of endoscopic screening for esophageal cancer in China (ESECC): design and preliminary results of a population-based randomised controlled trial. Gut 68, 198–206 (2019).

    PubMed  Google Scholar 

  27. Liu, Z. et al. A clinical model predicting the risk of esophageal high-grade lesions in opportunistic screening: a multicenter real-world study in China. Gastrointest. Endosc. 91, 1253–1260 (2020).

    PubMed  Google Scholar 

  28. Liu, M. et al. A model to identify individuals at high risk for esophageal squamous cell carcinoma and precancerous lesions in regions of high prevalence in China. Clin. Gastroenterol. Hepatol. 15, 1538–1546 (2017).

    PubMed  Google Scholar 

  29. Liu, M. et al. Update and validation of a diagnostic model to identify prevalent malignant lesions in esophagus in general population. EClinicalMedicine 47, 101394 (2022).

    PubMed  PubMed Central  Google Scholar 

  30. Xu, Z. et al. Efficient plasma metabolic fingerprinting as a novel tool for diagnosis and prognosis of gastric cancer: a large-scale, multicentre study. Gut 72, 2051–2067 (2023).

  31. Wang, P. et al. Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection. Sci. Transl. Med. 14, eabp8704 (2022).

    CAS  PubMed  Google Scholar 

  32. Chen, X. et al. Non-invasive early detection of cancer four years before conventional diagnosis using a blood test. Nat. Commun. 11, 3475 (2020).

    CAS  PubMed  PubMed Central  Google Scholar 

  33. Zhang, X. et al. Ultrasensitive and affordable assay for early detection of primary liver cancer using plasma cell-free DNA fragmentomics. Hepatology 76, 317–329 (2022).

    CAS  PubMed  Google Scholar 

  34. He, J. et al. [China guideline for the screening and early detection of lung cancer(2021, Beijing)]. Zhonghua Zhong Liu Za Zhi 43, 243–268 (2021).

    CAS  PubMed  Google Scholar 

  35. He, J. et al. [China guideline for the screening, early detection and early treatment of gastric cancer (2022, Beijing)]. Zhonghua Zhong Liu Za Zhi 44, 634–666 (2022).

    CAS  PubMed  Google Scholar 

  36. He, J. et al. [China guideline for the screening, early detection and early treatment of esophageal cancer (2022, Beijing)]. Zhonghua Zhong Liu Za Zhi 44, 491–522 (2022).

    CAS  Google Scholar 

  37. National Cancer Center, China, Expert Group of the Development of China Guideline for the Screening, Early Detection and Early Treatment of Colorectal Cancer. [China guideline for the screening, early detection and early treatment of colorectal cancer (2020, Beijing)]. Zhonghua Zhong Liu Za Zhi 43, 16–38 (2021).

  38. He, J. et al. [China guideline for the screening and early detection of female breast cancer(2021, Beijing)]. Zhonghua Zhong Liu Za Zhi 43, 357–382 (2021).

  39. The Chinese Anti-Cancer Association, Gynecological Oncology Professional Committee. [Guidelines for the diagnosis and treatment of cervical cancer (2021 edition)]. Zhonghua Zhong Liu Za Zhi 31, 474–489 (2021).

  40. Cao, S. M., Simons, M. J. & Qian, C. N. The prevalence and prevention of nasopharyngeal carcinoma in China. Chin. J. Cancer 30, 114–119 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Chang, Q. Y., Du, J. & Yu, D. Progression of aging population and cancer prevention and treatment in China. Chin. J. Cancer Prev. Treat. 29, 1165–1170 (2022).

    Google Scholar 

  42. Wang, F., Dong, X. & Li, N. A call to improve the quality of screening programs. Nat. Med. 29, 1062–1063 (2023).

    CAS  PubMed  Google Scholar 

  43. Fitzgerald, R. C., Antoniou, A. C., Fruk, L. & Rosenfeld, N. The future of early cancer detection. Nat. Med. 28, 666–677 (2022).

    CAS  PubMed  Google Scholar 

  44. Xi, S. et al. Magnetic controlled capsule endoscope (MCCE)‘s diagnostic performance for H. pylori infection status based on the Kyoto classification of gastritis. BMC Gastroenterol. 22, 502 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Zhang, Q. et al. China special issue on gastrointestinal tumors—improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: a multicenter, noninterventional, controlled study. Int. J. Cancer 153, 1885–1893 (2023).

    CAS  PubMed  Google Scholar 

  46. Li, J. et al. Expert consensus on multidisciplinary therapy of colorectal cancer with lung metastases (2019 edition). J. Hematol. Oncol. 12, 16 (2019).

  47. Wang, D., Mo, T., Xue, D., Shen, L. & Lu, M. Analysis of the first batch of national pilot hospitals for multidisciplinary diagnosis and treatment of cancer. Chin. Oncol. 30, 352–356 (2021).

    Google Scholar 

  48. Wen, T. et al. Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: an international expert consensus. Hepatobiliary Surg. Nutr. 7, 353–371 (2018).

    Google Scholar 

  49. Gastric Cancer Association, China Anti-Cancer Association. [Chinese expert consensus on perioperative treatment of locally advanced gastric cancer (2021 version)]. Zhonghua Wei Chang Wai Ke Za Zhi 24, 741–748 (2021).

  50. Song, P., Wu, Q. & Huang, Y. Multidisciplinary team and team oncology medicine research and development in China. Biosci. Trends 4, 151–160 (2010).

    PubMed  Google Scholar 

  51. Lu, J., Jiang, Y., Qian, M., Lv, L. & Ying, X. The improved effects of a multidisciplinary team on the survival of breast cancer patients: experiences from China. Int. J. Environ. Res. Public Health 17, 277 (2019).

    PubMed  PubMed Central  Google Scholar 

  52. Zhang, Q. et al. China special issue on gastrointestinal tumor-improved survival after multidisciplinary team decision for patients with advanced gastrointestinal cancer: a multicenter, noninterventional, controlled study. Int. J. Cancer 153, 1885–1893 (2023).

  53. Zhang, X. et al. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncol. 22, 1081–1092 (2021).

    CAS  PubMed  Google Scholar 

  54. Mok, T. S. et al. Improvement in overall survival in a randomized study that compared dacomitinib with gefitinib in patients with advanced non-small-cell lung cancer and EGFR-activating mutations. J. Clin. Oncol. 36, 2244–2250 (2018).

    CAS  PubMed  Google Scholar 

  55. Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).

    CAS  PubMed  Google Scholar 

  56. Andre, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207–2218 (2020).

    CAS  PubMed  Google Scholar 

  57. Wu, Y. L. et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 383, 1711–1723 (2020).

    CAS  PubMed  Google Scholar 

  58. Shao, Z. et al. Efficacy, safety, and tolerability of pertuzumab, trastuzumab, and docetaxel for patients with early or locally advanced ERBB2-positive breast cancer in Asia: The PEONY Phase 3 Randomized Clinical Trial. JAMA Oncol. 6, e193692 (2020).

    PubMed  Google Scholar 

  59. Lam, T. C. et al. Consensus statements on precision oncology in the China Greater Bay Area. JCO Precis. Oncol. 7, e2200649 (2023).

    PubMed  PubMed Central  Google Scholar 

  60. Wang, F. H. et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Commun. 41, 747–795 (2021).

    Google Scholar 

  61. Bi, W. L. et al. Artificial intelligence in cancer imaging: clinical challenges and applications. CA Cancer J. Clin. 69, 127–157 (2019).

    PubMed  PubMed Central  Google Scholar 

  62. Shao, L. et al. Regulatory watch: innovative drug availability in China. Nat. Rev. Drug Discov. 15, 739–740 (2016).

    CAS  PubMed  Google Scholar 

  63. The General Office of the Communist Party of China Central Committee and the General Office of the State Council. Opinions of the state council regarding deepening reforms on the examination and approval system, encouraging drug and medical device innovations. https://www.gov.cn/zhengce/2017-10/08/content_5230105.htm (2017).

  64. National Medical Products Administration. Policies on reforming clinical trial administrations and encouraging drug and medical device innovations. https://www.nmpa.gov.cn/xxgk/ggtg/zhggtg/20170511214401856.html (2017).

  65. National Health Commission of the People’s Republic of China. Administrative Measures for Clinical Research Initiated by Researchers in Medical and Health Institutions (Draft for Comments). www.cde.org.cn/main/news/viewInfoCommon/849b5a642142fc00738aff200077db11 (2021).

  66. Centre for Drug Evaluation NMPA. Launched drug information. https://www.cde.org.cn/main/xxgk/listpage/b40868b5e21c038a6aa8b4319d21b07d (accessed May 2023).

  67. Deeks, D. E. Disitamab vedotin: first approval. Drugs 81, 1929–1935 (2021).

    CAS  PubMed  Google Scholar 

  68. Janjigian, Y. Y. et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro–oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398, 27–40 (2021).

    CAS  PubMed  PubMed Central  Google Scholar 

  69. Kojima, T. et al. First-line pembrolizumab + chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590. Esophagus 19, 683–692 (2022).

    PubMed  PubMed Central  Google Scholar 

  70. Qin, S. et al. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 21, 571–580 (2020).

    CAS  PubMed  Google Scholar 

  71. Ren, Z. et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study. Lancet Oncol. 22, 977–990 (2021).

    CAS  PubMed  Google Scholar 

  72. Sun, J. M. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759–771 (2021).

    CAS  PubMed  Google Scholar 

  73. Wang, Z. X. et al. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell 40, 277–288 (2022).

    CAS  PubMed  Google Scholar 

  74. Felip, E. et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 398, 1344–1357 (2021).

    CAS  PubMed  Google Scholar 

  75. Paz-Ares, L. et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 394, 1929–1939 (2019).

    CAS  PubMed  Google Scholar 

  76. Shah, M. et al. FDA approval summary: pembrolizumab for neoadjuvant and adjuvant treatment of patients with high-risk early-stage triple-negative breast cancer. Clin. Cancer Res. 28, 5249–5253 (2022).

    CAS  PubMed  Google Scholar 

  77. Sheng, X. et al. Safety, efficacy, and biomarker analysis of toripalimab in patients with previously treated advanced urothelial carcinoma: results from a multicenter phase II trial POLARIS-03. Clin. Cancer Res. 28, 489–497 (2022).

    CAS  PubMed  Google Scholar 

  78. Yang, Y. et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 22, 1162–1174 (2021).

    CAS  PubMed  Google Scholar 

  79. Zhou, C. et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir. Med. 9, 305–314 (2021).

    CAS  PubMed  Google Scholar 

  80. Keam, S. J. Cadonilimab: first approval. Drugs 82, 1333–1339 (2022).

    CAS  PubMed  Google Scholar 

  81. Jiang, W., Wang, Z., Sheng, Z., Jung, J. & Taylor, G. TJ-CD4B (ABL111), a Claudin18.2-targeted 4-1BB tumor engager induces potent tumor-dependent immune response without dose-limiting toxicity in preclinical studies. J. Immunother. Cancer 9, A730 (2021).

    Google Scholar 

  82. Gong, J. et al. Safety results of Q-1802, a Claudin18.2/PD-L1 bsABs, in patients with relapsed or refractory solid tumors in a phase 1 study. J. Clin. Oncol. 40, abstract 2568 (2022).

  83. Wang, Y. et al. First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors. J. Clin. Oncol. 41, abstract 3016 (2023).

  84. Xu, R.-h et al. A phase 1a dose-escalation, multicenter trial of anti-claudin 18.2 antibody drug conjugate CMG901 in patients with resistant/refractory solid tumors. J. Clin. Oncol. 41, 352 (2023).

    Google Scholar 

  85. Chen, Y. et al. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment. Nat. Commun. 13, 4851 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Lam, W. C., Lyu, A. & Bian, Z. ICD-11: impact on traditional Chinese medicine and world healthcare systems. Pharmaceut. Med. 33, 373–377 (2019).

    CAS  PubMed  Google Scholar 

  87. Yuan, H., Ma, Q., Ye, L. & Piao, G. The traditional medicine and modern medicine from natural products. Molecules 21, 559 (2016).

  88. Liu, G. et al. Drug research and development opportunities in low- and middle-income countries: accelerating traditional medicine through systematic utilization and comprehensive synergy. Infect. Dis. Poverty 11, 27 (2022).

    PubMed  PubMed Central  Google Scholar 

  89. Wang, C. et al. Ferritin-based targeted delivery of arsenic to diverse leukaemia types confers strong anti-leukaemia therapeutic effects. Nat. Nanotechnol. 16, 1413–1423 (2021).

    PubMed  Google Scholar 

  90. Lamers, C. H. et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J. Clin. Oncol. 24, e20–e22 (2006).

    PubMed  Google Scholar 

  91. Kershaw, M. H. et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin. Cancer Res. 12, 6106–6115 (2006).

    CAS  PubMed  PubMed Central  Google Scholar 

  92. Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189–1198 (2022).

    CAS  PubMed  PubMed Central  Google Scholar 

  93. Yi, B. An overview of the Chinese healthcare system. Hepatobiliary Surg. Nutr. 10, 93–95 (2021).

    Google Scholar 

  94. Yu, H. Universal health insurance coverage for 1.3 billion people: what accounts for China’s success? Health Policy 119, 1145–1152 (2015).

    PubMed  PubMed Central  Google Scholar 

  95. Qian, J. Health reform in China: developments and future prospects. Health Care Sci. 1, 166–172 (2022).

Download references

Acknowledgements

This work was supported by the National Natural Science Foundation of China (U22A20327, 82203881, 91959205, 92159106, 82073230), the Beijing Natural Science Foundation (7222021), the Beijing Hospitals Authority Youth Programme (QMS20201102), and the Clinical Medicine Plus X-Young Scholars Project of Peking University (PKU2023LCXQ041). The funder had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank Z. He (Peking University Cancer Hospital and Institute) for providing valuable suggestions.

Author information

Author notes

  1. These authors contributed equally: Zhihao Lu, Yang Chen, Dan Liu.

Authors and Affiliations

  1. Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital and Institute, Beijing, China

    Zhihao Lu, Yang Chen, Dan Liu, Xi Jiao, Chang Liu, Yakun Wang, Zizhen Zhang, Keren Jia, Jifang Gong & Lin Shen

  2. National Center for Drug Evaluation, National Medical Products Administration, Beijing, China

    Zhimin Yang

Authors
  1. Zhihao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Xi Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chang Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yakun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Zizhen Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Keren Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jifang Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Zhimin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Lin Shen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

L.S. and Z.L. conceived and supervised the study. Y.C., D.L., Y.W., X.J., C.L. and Z.Z. contributed to data processing and integrative analyses. K.J., X.J., Y.C., D.L. and Z.Z. assisted with data processing and generating figures and tables. L.S., Z.L., Y.C., D.L., X.J., C.L., Z.Z. and Y.W. wrote the manuscript. L.S., Z.L., D.L., J.G., Y.C., C.L. and Z.Y. revised the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Lin Shen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Peer review

Peer review information

Nature Medicine thanks Stephen Chan, Emile Voest, and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary Handling Editor: Karen O’Leary, in collaboration with the Nature Medicine team.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lu, Z., Chen, Y., Liu, D. et al. The landscape of cancer research and cancer care in China. Nat Med 29, 3022–3032 (2023). https://doi.org/10.1038/s41591-023-02655-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02655-3

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing